Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Osteoporosis Drugs Market

Osteoporosis Drugs Market Share

Report ID: GMI9420
Published Date: May 2024
Report Format: PDF

Download Free Sample

Osteoporosis Drugs Market Share

The market offers a diverse array of pharmaceutical options to address the prevalent skeletal disorder characterized by decreased bone density and heightened fracture risk. Bisphosphonates like alendronate, risedronate, and zoledronic acid dominate market share due to their proven effectiveness in fracture reduction and bone health preservation. Emerging drug classes such as SERMs, parathyroid hormone analogs, and monoclonal antibodies like denosumab are gaining momentum, offering unique mechanisms, and promising clinical outcomes. Supported by an aging population and heightened osteoporosis awareness, the market experiences consistent growth, buoyed by ongoing drug development, expanded treatment options, and increasing healthcare investments worldwide. This trend is expected to continue as pharmaceutical innovation drives further market expansion.

Osteoporosis Drugs Market Companies

Prominent players operating in the osteoporosis drugs industry include:

Amgen Inc.
Apotex Inc.
Daiichi Sankyo Company, Limited
Eisai Co., Ltd.
Eli Lilly and Company
GSK plc
Merck & Co., Inc.
Mylan N.V.
Novartis AG
Pfizer Inc.
Radius Health, Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Limited
UCB S.A.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global osteoporosis drugs market was valued at USD 15.8 billion in 2023 and is expected to exhibit growth at 4.6% CAGR from 2024 – 2032, attributed to the ongoing advancements in medical technology.

The bisphosphonates drug type segment held 35% of the market share in 2023 and will grow rapidly by 2032, as the drug has demonstrated efficacy in reducing the risk of fractures in individuals with osteoporosis.

North America osteoporosis drugs market size recorded USD 5.9 billion market in revenue in 2023 and will grow at 4.3% CAGR between 2024 – 2032, owing to presence of an advanced healthcare infrastructure.

Amgen Inc., Apotex Inc., Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Eli Lilly and Company, GSK plc, and Merck & Co., Inc. among others.